ArticleClinical and translational science2026
Integrative Use of Ningmitai Capsule and Cefoxitin in Treating Post-Ureteroscopic Lithotripsy Stent-Related Urinary Tract Infections.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ureteral stent placement following ureteroscopic lithotripsy (URL) reduces obstruction but increases the risk of urinary tract infection (UTI). Conventional antibiotic therapy alone is often insufficient. Ningmitai capsule, a traditional Chinese herbal preparation, has demonstrated anti-inflammatory and antibacterial activity. This study evaluated the efficacy, safety, and translational value of combining Ningmitai with cefoxitin. A retrospective controlled study included 76 patients who developed UTI after URL with stent placement between May 2023 and October 2024. Patients were stratification-matched to a cefoxitin-only group (n = 38, cefoxitin only) or a combined group (n = 38, cefoxitin plus Ningmitai). Clinical efficacy, urinary symptom scores, inflammatory markers [high-sensitivity C-reactive protein (hs-CRP), interleukin-1β (IL-1β), procalcitonin (PCT)], and adverse reactions were compared. Logistic regression identified independent predictors, and decision curve analysis (DCA) assessed clinical net benefit. The combined group achieved a higher efficacy rate than the cefoxitin-only group (94.74% vs. 78.95%, p = 0.042). Dysuria, urinary frequency, hematuria, and renal colic improved more significantly, and hs-CRP, IL-1β, and PCT levels decreased to a greater extent in the combined group (all p < 0.001). Combination therapy was an independent predictor of success (OR = 4.52, 95% CI: 1.56-13.06). The predictive model improved AUC from 0.71 to 0.91. DCA showed superior net benefit between 0.1-0.5 thresholds. Adverse events were rare and comparable between groups. Ningmitai capsule combined with cefoxitin improves symptoms, reduces inflammation, and maintains safety in stent-associated UTI after URL. Predictive modeling and DCA confirm its translational potential as an integrative therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.